Hem › Blodcancer › Massachusetts › Boston
Kliniska studier för Blodcancer i Boston, MA
25 studier för Blodcancer söker deltagare vid platser i och runt Boston (inom ca 30 miles). Öppna en studie för att se vem som kan delta och hur du kontaktar studieteamet.
Officiell studietext (engelska)
Rekryterar du till en studie? Visa den högst upp på sidan – $99 i 30 dagar →
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
RekryterarFas 1/2
- Dana Farber Cancer Institute, Boston
Multidisciplinary Intervention for Adults With Chronic Graft-versus-host Disease
Rekryterar
- Massachusetts General Hospital, Boston
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
RekryterarFas 1
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
RekryterarObservationsstudie
- Brigham and Women's Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
SURGE: Supporting Utility and Representation in Genomics-based Cancer Trial Enrollment (Intervention)
Rekryterar
- Dana Farber Cancer Institute, Boston
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
RekryterarFas 2
- Dana-Farber Cancer Institute, Boston
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
RekryterarFas 1/2
- Massachusetts General Hospital, Boston
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
RekryterarFas 1
- Beth Israel Deaconess Medical Center, Boston
InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
RekryterarObservationsstudieFriska volontärer välkomna
- Dana Farber Cancer Institute, Boston
PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)
RekryterarFas 2
- Brigham and Women's Hospital, Boston
Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)
RekryterarFriska volontärer välkomna
- Dana-Farber Cancer Institute, Boston
Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies
RekryterarFas 3
- Tufts Medical Center, Boston
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
RekryterarObservationsstudie
- Tufts Medical Center, Boston
- Beth Israel Deaconess, Boston
- Dana Farber Cancer Institute, Boston
IVIG for Infection Prevention After CAR-T-Cell Therapy
RekryterarFas 2
- Massachusetts General Hospital Cancer Center, Boston
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
RekryterarObservationsstudie
- Dana-Farber Cancer Institute, Boston
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
RekryterarFas 1
- Dana Farber Cancer Institute, Boston
Feasibility and Acceptability of Primary Palliative Care Intervention in Patients Undergoing Hematopoietic Stem Cell Transplantation
Rekryterar
- Massachusetts General Hospital, Boston
Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
Rekryterar
- Massachusetts General Hospital Cancer Center, Boston
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
RekryterarFas 1/2
- Dana Farber Cancer Institute, Boston
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
RekryterarFas 1
- Massachusetts General Hospital, Boston
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
RekryterarFas 1/2
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
BMT-CARE: Psychosocial Intervention for Transplant Caregivers
Rekryterar
- Massachusetts General Hospital Cancer Center, Boston
HEME Home Transfusion Program
Rekryterar
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
RekryterarFas 1
- Dana-Farber Cancer Institute, Boston
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
RekryterarFas 1
- Dana-Farber Cancer Institute, Boston
Blodcancer-studier i andra städer
- Houston, TX46 studier
- New York City, NY26 studier
- Washington, DC19 studier
- Baltimore, MD18 studier
- Seattle, WA18 studier
- Los Angeles, CA17 studier
- Durham, NC16 studier
- Chicago, IL15 studier
- Philadelphia, PA14 studier
- Atlanta, GA13 studier
- Nashville, TN13 studier
- Edison, NJ13 studier
Andra studier i Boston
- Bröstcancer111 studier
- Icke-småcellig lungcancer90 studier
- Cancer (alla typer)86 studier
- Kolorektal cancer63 studier
- Metastaserande cancer63 studier
- Lungcancer62 studier
- Äggstockscancer61 studier
- Prostatacancer59 studier
- Depression52 studier
- Endometriecancer50 studier
- Hjärtsvikt44 studier
- Akut myeloid leukemi44 studier
Från ClinicalTrials.gov, data hämtad 5 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.